Anti-factor D antibodies
The invention relates to anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
1. An anti-Factor D antibody comprising a light chain variable domain amino acid sequence of SEQ ID NO:19, and a heavy chain variable domain amino acid sequence of SEQ ID NO:20.
2. An anti-Factor D antibody comprising: a light chain variable domain comprising a HVR-L1 having the sequence of SEQ ID NO: 14, a HVR-L2 having the sequence of SEQ ID NO:6, and a HVR-L3 having the sequence of SEQ ID NO:7; and a heavy chain variable domain comprising a HVR-H1 having the sequence of SEQ ID NO:8, a HVR-H2 having the sequence of SEQ ID NO:12, and a HVR-H3 having the sequence of SEQ ID NO:15.
3. An anti-Factor D antibody having a light chain having the amino acid sequence of SEQ ID NO: 28 and a heavy chain having the amino acid sequence of SEQ ID NO: 29.
4. A pharmaceutical formulation comprising the antibody according to any one of claim 1 , 2 and 3 .
5. The pharmaceutical formulation according to claim 4 , wherein the antibody is at a concentration of at least 100 mg/ml.
6. The pharmaceutical formulation according to claim 4 , wherein the antibody is at a concentration of at least 200 mg/ml.
7. The pharmaceutical formulation according to claim 4 , wherein the antibody is at a concentration of at least 300 mg/ml.
8. The pharmaceutical formulation according to claim 4 , wherein the antibody is at a concentration of at least 500 mg/ml.
9. A kit comprising an anti-Factor D antibody of any one of claim 1 , 2 and 3 .